<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hetastarch (Hydroxyethyl starch; Hespan, Hextend): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hetastarch (Hydroxyethyl starch; Hespan, Hextend): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Hetastarch (Hydroxyethyl starch; Hespan, Hextend): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11377" href="/d/html/11377.html" rel="external">see "Hetastarch (Hydroxyethyl starch; Hespan, Hextend): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13350" href="/d/html/13350.html" rel="external">see "Hetastarch (Hydroxyethyl starch; Hespan, Hextend): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F50370214"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Mortality, kidney injury, and coagulopathy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of hydroxyethyl starch (HES) products increases the risk of mortality, kidney injury, and coagulopathy.</p>
<p style="text-indent:-2em;margin-left:2em;">Do not use HES products (ie, hetastarch) unless adequate alternative treatment is unavailable.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F179043"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Hespan;</li>
<li>Hextend</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F179076"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Plasma Volume Expander, Colloid</li></ul></div>
<div class="block doa drugH1Div" id="F179046"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cb68576b-08a7-4fe2-a5d4-9268376f9b0f">Granulocyte yield increase</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Granulocyte yield increase (Hespan) (adjunctive agent):</b> 250 to 700 mL; <b>Note:</b> Citrate anticoagulant is added before use and then the mixture is administered to the input line of the centrifuge apparatus.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9ac070fb-1ce3-45bd-922b-7460a67d713e">Plasma volume expansion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plasma volume expansion:</b>
<b>Note:</b> Discontinue use at the first sign of kidney injury. Do not use in the critically ill, those with sepsis or septic shock, those undergoing open heart surgery and cardiopulmonary bypass, or those with preexisting kidney impairment (SSC [Evans 2021]; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 500 to 1,000 mL once; may repeat as needed based on assessment of intravascular volume status. Doses of more than 1,500 mL/day (~20 mL/kg) are usually not required.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990642"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Avoid use in patients with preexisting kidney impairment. Discontinue use at the first sign of kidney injury. Not eliminated by hemodialysis.</p></div>
<div class="block doha drugH1Div" id="F50987839"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doe drugH1Div" id="F179047"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F52812514"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13350" href="/d/html/13350.html" rel="external">see "Hetastarch (Hydroxyethyl starch; Hespan, Hextend): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> With severe dehydration, administer crystalloid first. Dose and rate of infusion are dependent on amount of blood lost, on maintenance or restoration of hemodynamics, and on amount of hemodilution. Titrate to individual colloid needs, hemodynamics, and hydration status. Do not use in critically ill patients, those undergoing open heart surgery with cardiopulmonary bypass, or those with preexisting kidney dysfunction. Critical Care Medicine societies (ACCM, SCCM) recommend against the use of hydroxyethyl starch (HES) solutions for fluid resuscitation of severe sepsis and septic shock in neonatal and pediatric patients (ACCM [Davis 2017]; SCCM [Dellinger 2013]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3580eebd-40a6-426b-b15a-00c1e9547c06">Volume expansion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Volume expansion:</b> Very limited data available: IV infusion: Children ≥1 year and Adolescents: 10 mL/kg/dose; dosing based on a small randomized, double-blinded study of 38 patients (age range: 1 to 15.5 years) compared hetastarch (n=20) and albumin (n=18) as a postoperative volume expander in the first 24 hours after congenital heart surgery; no differences in safety compared to albumin were found at hetastarch daily doses ≤20 mL/kg/day; patients receiving doses of 20 to 30 mL/kg/day were noted to have an increased PT; however, there was no difference in clinical bleeding; doses &gt;30 mL/kg have not been studied (Brutocao 1996).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F52729731"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendation available; based on experience in adults, avoid use in patients with pre-existing renal dysfunction; use is contraindicated in renal failure with oliguria or anuria (not related to hypovolemia) and use should be discontinued at the first sign of renal injury.</p></div>
<div class="block dohp drugH1Div" id="F52729732"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; based on experience in adult patients, use with caution.</p></div>
<div class="block adr drugH1Div" id="F179017"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased plasma volume</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypervolemia, increased amylase (transient), metabolic acidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Disorder of hemostatic components of blood (including Factor VIII deficiency, acquired von Willebrand's-like syndrome, dilutional coagulopathy), hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased indirect serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, angioedema, chest pain, erythema multiforme, fever, nonimmune anaphylaxis, severe hypotension, ventricular fibrillation)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart failure, lower extremity edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Parotid gland enlargement, submaxillary gland enlargement, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, disseminated intravascular coagulopathy (rare), hemolysis (rare), prolonged bleeding time</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache, intracranial hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Lagny 2016, Zarychanski 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms, pulmonary edema</p></div>
<div class="block coi drugH1Div" id="F179030"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">In patients when adequate alternative treatment is available.</p></div>
<div class="block war drugH1Div" id="F179014"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid reactions: Life-threatening anaphylactic/anaphylactoid reactions, including death, have been reported (rarely); discontinue use immediately with signs of hypersensitivity and administer appropriate therapy. Patients allergic to corn may be allergic to hetastarch.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding/coagulopathy: Discontinue use of hydroxyethyl starch (HES) at the first sign of coagulopathy. Not recommended for use as a cardiac bypass pump prime, while the patient is on cardiopulmonary bypass, or in the period immediately afterward. HES solutions have been associated with excess bleeding in these patients. Monitor the coagulation status in patients undergoing open heart surgery in association with cardiopulmonary bypass. May cause coagulation abnormalities in conjunction with a reversible, acquired von Willebrand-like syndrome and/or factor VIII deficiency when used over a period of days. Consider replacement therapy if a severe factor VIII deficiency is detected. Coagulopathies may take several days to resolve. When used to prevent cerebral vasospasm in patients with subarachnoid hemorrhage (off-label use), significant clinical bleeding, intracranial bleeding, and death have been reported. Monitor the coagulation status of surgery patients due to excess bleeding with the administration of HES in this population.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid overload: Administration may cause fluid overload; use with caution in patients at risk from overexpansion of blood volume (eg, very young, older patients).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic: Large volumes of hetastarch may cause a reduction in hemoglobin concentration, coagulation factors, and other plasma proteins due to hemodilution; when used for leukapheresis, frequent clinical evaluation and complete blood counts (CBC) are recommended. If leukapheresis frequency is greater than whole blood donation guidelines, consider monitoring total leukocyte and platelet counts, leukocyte differential, PT, and PTT as well. Coagulation may be impaired (eg, prolonged PT, PTT, and clotting times) and a transient prolongation of bleeding time may be observed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Avoid use in patients with preexisting kidney impairment; monitor fluid status, urine output, and infusion rate; discontinue use at the first sign of kidney injury. Larger hetastarch molecules may leak into urine in patients with glomerular damage; may elevate urine specific gravity. Since the need for renal replacement therapy has been reported up to 90 days after HES administration, continue to monitor kidney function in all patients for at least 90 days.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombocytopenia: Use with caution in patients with thrombocytopenia; large volumes may interfere with platelet function and transiently prolong bleeding time. Observe for bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Critically ill patients: Avoid use in critically ill adult patients, including those with sepsis and those admitted to the ICU. HES solutions have been associated with an increased risk of mortality in the critically ill (Brunkhorst 2008; Perel 2012; Perner 2012; SSC [Evans 2021]). Crystalloids (eg, sodium chloride and balanced solutions) are recommended as the fluid of choice for initial resuscitation and ongoing resuscitation (SSC [Evans 2021]. Avoid use in patients with preexisting kidney impairment and discontinue use at the first sign of kidney injury. Since the need for renal replacement therapy has been reported up to 90 days after HES administration, continue to monitor kidney function in all patients for at least 90 days.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hextend: Contains calcium, lactate and potassium; use with caution in situations where electrolyte and/or acid-base disturbances may be exacerbated (kidney impairment, respiratory alkalosis, metabolic alkalosis). Do not use in leukapheresis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not a substitute for red blood cells or coagulation factors.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878482"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Hetastarch use has been associated with acute kidney injury in pediatric patients (Reinhart 2012).</p></div>
<div class="block foc drugH1Div" id="F179025"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hespan: 6% (500 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hextend: 6% (500 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 6% (500 mL)</p></div>
<div class="block geq drugH1Div" id="F179010"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323182"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Hespan Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6-0.9% (per mL): $0.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Hetastarch-NaCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6-0.9% (per mL): $0.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Hextend Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6% (per mL): $0.23</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F179027"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Plasma volume expansion: Administer IV only; may be administered via infusion pump or pressure infusion. Administration rates vary depending upon the extent of blood loss, age, and clinical condition of patient but, <i>in general</i>, should not exceed 1.2 g/kg/hour (20 mL/kg/hour); <i>however, </i>
<b>rates up to 1,000 mL over 7 to 8 minutes via pressure infusion have been studied in otherwise healthy subjects (McIlroy 2003)</b>. Anaphylactoid reactions can occur, have epinephrine and resuscitative equipment available. If administered by pressure infusion, air should be withdrawn or expelled from bag prior to infusion to prevent air embolus. Do not administer Hextend with blood through the same administration set. Change IV tubing or flush copiously with normal saline before administering blood through the same line. Change IV tubing at least every 24 hours. Do not use if crystalline precipitate forms or is turbid deep brown.</p>
<p style="text-indent:-2em;margin-left:2em;">Granulocyte yield increase: Mix Hespan and citrate well. Administer to the input line of the centrifuge apparatus at a ratio of 1:8 to 1:13 to venous whole blood.</p></div>
<div class="block admp drugH1Div" id="F52612979"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: <b>Volume expansion:</b> IV: Administer IV only; may be administered via infusion pump or pressure infusion; if administered by pressure infusion, air should be withdrawn or expelled from bag prior to infusion to prevent air embolus. Administration rates vary depending upon the extent of blood loss, age, and clinical condition of patient but, in general, should not exceed 1.2 <b>g</b>/kg/<b>hour</b> (20 mL/kg/<b>hour</b>) in adults. Change IV tubing or flush copiously with normal saline before administering blood through the same line. Do not administer Hextend with blood through the same administration set. Change IV tubing at least every 24 hours. Anaphylactoid reactions can occur; have epinephrine and resuscitative equipment available. Do not use if crystalline precipitate forms or is turbid deep brown.</p></div>
<div class="block use drugH1Div" id="F179026"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Granulocyte yield increase (Hespan only):</b> Adjunct in leukapheresis to improve harvesting and increase the yield of granulocytes by centrifugation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Plasma volume expansion:</b> Treatment of hypovolemia to expand plasma volume in settings where adequate alternative treatment is unavailable.</p></div>
<div class="block mst drugH1Div" id="F179084"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Hespan may be confused with heparin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299443"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6220790"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Arbekacin: Hetastarch may enhance the nephrotoxic effect of Arbekacin. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F13888219"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in some animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F20614016"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if hetastarch is present in breast milk. The manufacturer recommends that caution be exercised when administering hetastarch to breastfeeding women.</p></div>
<div class="block mop drugH1Div" id="F179023"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Plasma volume expansion: Assessment of intravascular volume status; BP, heart rate, urine output/kidney function (continue to monitor for at least 90 days after administration); serum electrolytes; acid-base balance; hemoglobin, hematocrit, coagulation parameters (especially in surgery patients), LFTs.</p>
<p style="text-indent:-2em;margin-left:2em;">Granulocyte yield increase: CBC, total leukocyte and platelet counts, leukocyte differential count, hemoglobin, hematocrit, PT, PTT.</p></div>
<div class="block pha drugH1Div" id="F179013"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Produces plasma volume expansion by virtue of its highly colloidal starch structure</p></div>
<div class="block phk drugH1Div" id="F179029"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Duration: 3 to 36 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~33% within 24 hours); smaller molecular weight molecules (&lt;50,000 daltons) rapidly excreted.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038650"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Haes steril | Hestar 200</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Haes | Hessico | Lorihess | Voluven</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Elohaest isoton nacl | Expahes | Haes steril | Voluven</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Voluven</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Voluven</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Elohaes | Voluven</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Haes steril</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Expan | Haes steril | Istarhes | Plasmin | Venofundin | Voluven</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Haes steril | Voluven</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Haes-steril | Hetastarch 40 | Huo mu | Voluven</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Hestar | Hidroxietil almidon | Nirhes | Nirhes 200 | Voluven</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Elohaest | Haes steril | Voluven</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Haes steril</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Voluven</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Refortan | Stabisol | Voluven</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Haes steril</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Elohes | Hes | Hesteril | Hidroxietil almidon | Voluven</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Voluven</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Heafusine | Hesteril | Pentastarch | Plasmohes | Voluven</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Elohaes | Haes steril | Hespan | Hespan ahs | Pentaspan | Venofundin | Voluven</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Haes steril | Voluven</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Voluven</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Elohast | Expahes | Haes steril | Isohes | Osmohes | Plasmasteril | Voluven</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Farhes | Haes steril | Haes Steril Askes | Haes Steril Reg | Sanbe hest</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Voluven</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Haes steril | Hestar | Ivstarch | Tetrahes</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Amidolite | Haes steril | Pentastarch | Voluven</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Hespander | Hestatt | Salinhes | Voluven</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Haes steril | Hestar 200 | Voluven</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Haes steril | Hemotasol | Hemotomin | Hesplasma | Hetastach | Hextend | Jeil pentastarch | Pentaspan | Pentastarch | Pentastarch in saline | Salinhes | Tetrahes | Voluven</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Haes steril | Voluven</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Refortan | Stabisol | Voluven</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Haes steril</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Refortan | Stabisol | Voluven</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Hestar | Tetrastar | Voluven</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Haes steril | Voluven</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Elohaes | Haes steril</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Voluven</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Pentaspan | Voluven</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Haes steril | Sanbe hest | Tetrahes</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Haes steril</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Haes steril | Hes-hemodil | Hydroksyetyloskrobia | Plasmasteril | Voluven</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Hespan | Hextend | Pentaspan</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Hessico | Hidroxietil almidon demotek</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Refortan | Refortan plus</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Haes steril | Hemohes | Hydrael 130 | Hydrael 200 | Hydroxyethyl starch 130 alium | Hydroxyethyl starch 200 | Hydroxyethyl starch 200 alium | Hydroxyethyl starch 200/0.5 | Hydroxyethylstarch | Ionokhes | Plasmaline | Plasmastabil 200 | Refortan | Refortan Hes | Refortan plus | Reohes 130 | Reohes 200 | Stabisol Hes | Volecam | Volecam haec | Volemcor | Voluven</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Plasma steril | Voluven</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Haes steril | Voluven</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Haes steril | Voluven</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Elohast | Haes steril | Voluven</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Haes steril | Hespander | Hestar | Tetrahes | Voluven</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Biohes | Bioplazma | Expahes | Haes steril | Isohes | Plasmasteril | Varihes | Voluhes</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">6-h.e.s. | Haes steril | Hesta | Hestar 200 pentastarch | Pentamo</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Geokodez | Haes steril | Hestar | Refordes | Refortan | Refortan N Hes | Refortan plus | Venofundin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Sanbe hest</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Haes steril</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Hestar</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Voluven</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Hestar | Voluven</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Hestar 200 | Voluven</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Bick RL, “Evaluation of a New Hydroxyethyl Starch Preparation (Hextend™) on Selected Coagulation Parameters,” <i>Clin Appl Thrombosis/Hemostasis</i>, 1995, 1(3):215-29.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18184958">
<a name="18184958"></a>Brunkhorst FM, Engel C, Bloos F, et al, “Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis,” <i>N Engl J Med</i>, 2008, 358(2):125-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/18184958/pubmed" id="18184958" target="_blank">18184958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8725415">
<a name="8725415"></a>Brutocao D, Bratton SL, Thomas JR, et al, “Comparison of Hetastarch With Albumin for Postoperative Volume Expansion in Children After Cardiopulmonary Bypass,” <i>J Cardiothorac Vasc Anesth</i>, 1996, 10(3):348-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/8725415/pubmed" id="8725415" target="_blank">8725415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11115448">
<a name="11115448"></a>Canver CC and Nichols RD, “Use of Intraoperative Hetastarch Priming During Coronary Bypass,” <i>Chest</i>, 2000, 118(6):1616-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/11115448/pubmed" id="11115448" target="_blank">11115448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28509730">
<a name="28509730"></a>Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. <i>Crit Care Med</i>. 2017;45(6):1061-1093.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/28509730/pubmed" id="28509730" target="_blank">28509730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23353941">
<a name="23353941"></a>Dellinger RP, Levy MM, Rhodes A, et al, "Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012," <i>Crit Care Med</i>, 2013, 41(2):580-637.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/23353941/pubmed" id="23353941" target="_blank">23353941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. <i>Crit Care Med</i>. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34599691">
<a name="34599691"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. <i>Intensive Care Med</i>. 2021:1-67. doi:10.1007/s00134-021-06506-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/34599691/pubmed" id="34599691" target="_blank">34599691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31696249">
<a name="31696249"></a>Fleischhacker E, Trentzsch H, Kuppinger D, et al. Fluid resuscitation after severe trauma injury : U-shaped associations between tetrastarch dose and survival time or frequency of acute kidney failure. Therapie des Volumenmangelschocks nach Polytrauma : U-förmige Assoziation zwischen Tetrastärke(HES)-Dosis und Überlebenszeit bzw. Häufigkeit eines akuten Nierenversagens. <i>Med Klin Intensivmed Notfmed</i>. 2020;115(7):591-599. doi:10.1007/s00063-019-00625-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/31696249/pubmed" id="31696249" target="_blank">31696249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10320157">
<a name="10320157"></a>Gan TJ, Bennett-Guerrero E, Phillips-Bute B, et al “Hextend®, a Physiologically Balanced Plasma Expander for Large Volume Use in Major Surgery: A Randomized Phase III Clinical Trial,” <i>Anesth Analg</i>, 1999, 88(5):992-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/10320157/pubmed" id="10320157" target="_blank">10320157</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Gan TJ, Wright D, Robertson C, et al, “Randomized Comparison of the Coagulation Profile When Hextend or 5% Albumin is Used for Intraoperative Fluid Resuscitation,” <i>Anesthesiology</i>, 2001, 95:A193.</div>
</li>
<li>
<div class="reference">
                  Hespan (hetastarch) [prescribing information]. Bethlehem, PA: B. Braun Medical Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hextend.1">
<a name="Hextend.1"></a>Hextend (hetastarch) [prescribing information]. Lake Forest, IL: Hospira Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10735779">
<a name="10735779"></a>Knutson JE, Deering JA, Hall FW, et al, “Does Intraoperative Hetastarch Administration Increase Blood Loss and Transfusion Requirements After Cardiac Surgery?” <i>Anesth Analg</i>, 2000, 90(4):801-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/10735779/pubmed" id="10735779" target="_blank">10735779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26774199">
<a name="26774199"></a>Lagny MG, Roediger L, Koch JN, et al. Hydroxyethyl starch 130/0.4 and the risk of acute kidney injury after cardiopulmonary bypass: a single-center retrospective study. <i>J Cardiothorac Vasc Anesth</i>. 2016;30(4):869-875. doi:10.1053/j.jvca.2015.10.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/26774199/pubmed" id="26774199" target="_blank">26774199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12760977">
<a name="12760977"></a>McIlroy DR and Kharasch ED. Acute intravascular volume expansion with rapidly administered crystalloid or colloid in the setting of moderate hypovolemia. <i>Anesth Analg.</i> 2003;96:1572-1577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/12760977/pubmed" id="12760977" target="_blank">12760977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24066745">
<a name="24066745"></a>Myburgh JA, Mythen MG. Resuscitation fluids. <i>N Engl J Med. </i>2013;369;13:1243-1251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/24066745/pubmed" id="24066745" target="_blank">24066745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23075127">
<a name="23075127"></a>Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. <i>N Engl J Med.</i> 2012;367;20:1901-1911.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/23075127/pubmed" id="23075127" target="_blank">23075127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20953964">
<a name="20953964"></a>Niemi TT, Miyashita R, and Yamakage M, “Colloid Solutions: A Clinical Update,” <i>J Anesth</i>, 2010, 24(6):913-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/20953964/pubmed" id="20953964" target="_blank">20953964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22696320">
<a name="22696320"></a>Perel P and Roberts I, “Colloids versus Crystalloids for Fluid Resuscitation in Critically Ill Patients,” <i>Cochrane Database Syst Rev</i>, 2012, 6:CD000567.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/22696320/pubmed" id="22696320" target="_blank">22696320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22738085">
<a name="22738085"></a>Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl Starch 130/0.4 versus Ringer's Acetate in Severe Sepsis [published correction appears in <i>N Engl J Med</i>. 2012;367(5):481]. <i>N Engl J Med</i>. 2012;367(2):124-134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/22738085/pubmed" id="22738085" target="_blank">22738085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24100337">
<a name="24100337"></a>Rasmussen KC, Johansson PI, Højskov M, et al. Hydroxyethyl starch reduces coagulation competence and increases blood loss during major surgery: results from a randomized controlled trial. <i>Ann Surg</i>. 2014;259(2):249-254. doi:10.1097/SLA.0000000000000267<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/24100337/pubmed" id="24100337" target="_blank">24100337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22323076">
<a name="22323076"></a>Reinhart K, Perner A, Sprung CL, et al, “Consensus Statement of the ESICM Task Force on Colloid Volume Therapy in Critically Ill Patients,” <i>Intensive Care Med</i>, 2012, 38(3):368-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/22323076/pubmed" id="22323076" target="_blank">22323076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28101605">
<a name="28101605"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/28101605/pubmed" id="28101605" target="_blank">28101605</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  University Health System Consortium. <i>Technology Assessment: Albumin, Nonprotein Colloid, and Crystalloid Solutions</i>, May 2000.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28077532">
<a name="28077532"></a>Vives M, Callejas R, Duque P, et al. Modern hydroxyethyl starch and acute kidney injury after cardiac surgery: a prospective multicentre cohort. <i>Br J Anaesth</i>. 2016;117(4):458-463. doi:10.1093/bja/aew258<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/28077532/pubmed" id="28077532" target="_blank">28077532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11867371">
<a name="11867371"></a>Wilkes NJ, Woolf RL, Powanda MC, et al, “Hydroxyethyl Starch in Balanced Electrolyte Solution (Hextend®) - Pharmacokinetic and Pharmacodynamic Profiles in Healthy Volunteers,” <i>Anesth Analg</i>, 2002, 94(3):538-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/11867371/pubmed" id="11867371" target="_blank">11867371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23423413">
<a name="23423413"></a>Zarychanski R, Abou-Setta AM, Turgeon AF, et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. <i>JAMA</i>. 2013;309(7):678-688. doi:10.1001/jama.2013.430<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hetastarch-hydroxyethyl-starch-hespan-hextend-drug-information/abstract-text/23423413/pubmed" id="23423413" target="_blank">23423413</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8522 Version 186.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
